<DOC>
	<DOCNO>NCT02446405</DOCNO>
	<brief_summary>The purpose study determine effectiveness enzalutamide , versus conventional non-steroidal anti androgen ( NSAA ) , combine luteinizing hormone release hormone analog ( LHRHA ) surgical castration , first line androgen deprivation therapy ( ADT ) newly diagnose metastatic prostate cancer .</brief_summary>
	<brief_title>Enzalutamide First Line Androgen Deprivation Therapy Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Men start first line androgen deprivation therapy metastatic prostate cancer . Inclusion criterion : 1 . Male age 18 old metastatic adenocarcinoma prostate 2 . Target nontarget lesion accord Response Evaluation Criteria Solid Tumours ( RECIST ) 1.1 3 . Adequate bone marrow function : Haemoglobin ( Hb ) ≥100g/L White Cell Count ( WCC ) ≥ 4.0 x 109/L platelet ≥100 x 109/L . 4 . Adequate liver function : Alanine transaminase ( ALT ) &lt; 2 x Upper Limit Normal ( ULN ) bilirubin &lt; 1.5 x ULN , ( bilirubin 1.52 x ULN , must normal conjugated bilirubin ) . If liver metastasis present ALT must &lt; 5 x ULN 5 . Adequate renal function : calculated creatinine clearance &gt; 30 ml/min ( CockcroftGault ) 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Patients performance status 2 eligible decline performance status due metastatic prostate cancer . 7 . Study treatment plan able start within 7 day randomisation . 8 . Willing able comply study requirement , include treatment required assessment 9 . Has complete baseline HealthRelated Quality Life ( HRQL ) questionnaires UNLESS unable complete limit literacy vision 10 . Signed , write , inform consent 1 . Prostate cancer significant sarcomatoid spindle cell neuroendocrine small cell component 2 . History seizure condition may predispose seizure ( e.g. , prior cortical stroke significant brain trauma ) . loss consciousness transient ischemic attack within 12 month randomization significant cardiovascular disease within last 3 month include : myocardial infarction , unstable angina , congestive heart failure , ongoing arrhythmia Grade &gt; 2 [ National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE ) , version 4.03 ] , thromboembolic event ( e.g. , deep vein thrombosis , pulmonary embolism ) . Chronic stable atrial fibrillation stable anticoagulant therapy allow . 3 . Life expectancy le 12 month . 4 . History another malignancy within 5 year prior randomisation , except either non melanomatous carcinoma skin , adequately treat , nonmuscleinvasive urothelial carcinoma bladder ( Tis , Ta low grade T1 tumour ) . 5 . Concurrent illness , include severe infection might jeopardize ability patient undergo procedure outline protocol reasonable safety . Human Immunodeficiency Virus ( HIV ) infection exclusion criterion control antiretroviral drug unaffected concomitant enzalutamide . 6 . Presence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule , include alcohol dependence drug abuse ; 7 . Patients sexually active willing/able use medically acceptable form barrier contraception . 8 . Prior ADT prostate cancer ( include bilateral orchidectomy ) , except follow setting : Started less 12 week prior randomisation AND Prostate Specific Antigen ( PSA ) stable fall . The 12 week start whichever following occurs early : first dose oral anti androgen , LHRHA , surgical castration . In adjuvant setting , completion adjuvant hormonal therapy 12 month prior randomisation AND total duration hormonal treatment exceed 24 month . For depot preparation , hormonal therapy deem start first dose complete next dose would otherwise due , e.g . 12 week last dose depot goserelin 10.8mg . 9 . Prior cytotoxic chemotherapy prostate cancer , 2 cycle docetaxel chemotherapy metastatic disease permit . 10 . Participation clinical trial investigational agent treatment prostate cancer disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic prostate cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>prostate cancer treatment</keyword>
	<keyword>enzalutamide</keyword>
</DOC>